|Phone||+43 (0) 1 - 236 657 611|
|Series B, 10/11 |
SHS Gesellschaft für Beteiligungsmanagement mbH
Earlybird Venture Capital
|Grant, 2/12 |
Austrian Research Promotion Agency
Based in Vienna, Austria, privately held Miracor is commercializing a unique and potentially disruptive technology, PICSOÂ®, for acute coronary syndrome (ACS), heart failure, and cardiac surgery patients. The Companyâ€™s objective is to establish PICSOÂ® as the standard of care for heart attack patients, thereby improving their quality of life. The initial market opportunity for PICSOÂ® is 30% of all ACS patients treated per year, which translates into more than 350,000 patients in the U.S. and Europe.
The Miracor PICSOÂ® Impulse System is CE-marked and can be used during coronary revascularization procedures following myocardial infarction and other types of acute coronary syndromes to intermittently increase the pressure in the coronary venous system. The technology is for investigational use only in the United States at this time.